secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2022-10-07T23:59:59+00:00
Accession:  0001683168-22-006803
Event type: leadership
Sentiment:  negative
Materiality: 0.80
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte CEO resigns; interim CEO appointed; Board forms Business Review Committee to evaluate strategic options
--------------------------------------------------------------------------------

- CEO Kenneth Waggoner resigned effective Oct 6; separation agreement provides $216,667 lump sum and $433,333 consulting payments over 12 months.
- Board appointed Joshua Silverman as interim CEO and Chairman; Silverman is a director since Aug 2022 and co-founder of Parkfield Funding.
- Board's Business Review Committee to evaluate opportunities including FDA clinical hold on Cell-in-a-Box IND and relationship with SG Austria.
- Company continuing share repurchase program of up to $10 million; spending on programs curtailed pending review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822006803/0001683168-22-006803-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822006803/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-006803

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer